{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:34:39Z","timestamp":1793705679242,"version":"4.5.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.vaccine.2019.12.042","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T08:58:04Z","timestamp":1578301084000},"page":"3610-3617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals"],"prefix":"10.1016","volume":"38","author":[{"given":"J.","family":"Burkhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hasler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Niedrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Villiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1149-1389","authenticated-orcid":false,"given":"S.","family":"B\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.042_b0005","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1016\/j.vaccine.2014.07.021","article-title":"Duration of post-vaccination immunity against yellow fever in adults","volume":"32","author":"Collaborative group for studies on yellow fever vaccines","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.042_b0010","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/B978-1-4557-0090-5.00043-4","article-title":"Yellow fever vaccine","author":"Monath","year":"2013","journal-title":"Vaccines Sixth Ed."},{"key":"10.1016\/j.vaccine.2019.12.042_b0015","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.042_b0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/jtm.12184","article-title":"Travelers with immune-mediated inflammatory diseases: are they different?","volume":"22","author":"Jaeger","year":"2015","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2019.12.042_b0025","first-page":"895","article-title":"Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.12.042_b0030","doi-asserted-by":"crossref","DOI":"10.1086\/597006","article-title":"Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients","author":"Veit","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.042_b0035","doi-asserted-by":"crossref","unstructured":"Lindsey NP, Horiuchi KA, Fulton C, Panella AJ, Kosoy OI, Velez JO, et al. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. J Travel Med 2018. doi:10.1093\/jtm\/tay108.","DOI":"10.1093\/jtm\/tay108"},{"key":"10.1016\/j.vaccine.2019.12.042_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix960","article-title":"Long-term immune response to yellow fever vaccination in human immunodeficiency virus (HIV)-infected individuals depends on HIV RNA suppression status: implications for vaccination schedule","author":"Veit","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.042_b0045","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jinf.2016.02.017","article-title":"17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients","volume":"72","author":"Wieten","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2019.12.042_b0050","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-012-0972-y","article-title":"Immunological memory protective immunity","author":"Zinkernagel","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.vaccine.2019.12.042_b0055","doi-asserted-by":"crossref","DOI":"10.1111\/imr.12648","article-title":"What if protective immunity is antigen\u2014driven and not due to so-called \u201cmemory\u201d B and T cells?","author":"Zinkernagel","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2019.12.042_b0060","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2017.04.014","article-title":"Protective and pathogenic memory plasma cells","author":"Hoyer","year":"2017","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2019.12.042_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2015.01.017","article-title":"Differentiation and maintenance of long-lived plasma cells","author":"Kometani","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0075","doi-asserted-by":"crossref","DOI":"10.1002\/eji.201142306","article-title":"The early cellular signatures of protective immunity induced by live viral vaccination","author":"Kohler","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2007.09.002","article-title":"Antibodies and B cell memory in viral immunity","author":"D\u00f6rner","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2019.12.042_b0085","article-title":"Immunological memory and protective immunity: understanding their relation","volume":"80","author":"Ahmed","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.12.042_b0090","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1056\/NEJM196911202812107","article-title":"Disorders of immunoglobulin metabolism","volume":"281","author":"Waldmann","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.042_b0095","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0100","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","author":"DiLillo","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0105","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/35036600","article-title":"Memory B-cell persistence is independent of persisting immunizing antigen","volume":"407","author":"Maruyama","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.12.042_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/nri1886","article-title":"Competence and competition: the challenge of becoming a long-lived plasma cell","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0115","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.vaccine.2016.01.027","article-title":"Diverse effects on vaccine-specific serum IgG titres and memory B cells upon methotrexate and anti-TNF-\u03b1 therapy in children with rheumatic diseases: a cross-sectional study","volume":"34","author":"Ingelman-Sundberg","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.042_b0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaut.2012.05.010","article-title":"Bone marrow of NZB\/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: Implications for the treatment of autoimmunity","volume":"39","author":"Mumtaz","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2019.12.042_b0125","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W Mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.12.042_b0130","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.4049\/jimmunol.1003319","article-title":"Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation","volume":"187","author":"Karnell","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2613.2011.00800.x","article-title":"Deregulation of the CXCL12\/CXCR4 axis in methotrexate chemotherapy-induced damage and recovery of the bone marrow microenvironment","volume":"93","author":"Georgiou","year":"2012","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2008.098418","article-title":"How to cope with pathogenic long-lived plasma cells in autoimmune diseases","volume":"67","author":"Hoyer","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2019.12.042_b0145","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez045","article-title":"Safety and immunogenicity of tetanus\/diphtheria vaccination in patients with rheumatic diseases\u2014a prospective multi-centre cohort study","author":"B\u00fchler","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.vaccine.2019.12.042_b0150","article-title":"Voyageur immunosupprim\u00e9: recommandations vaccinales","author":"Eperon","year":"2018","journal-title":"Rev Med Suisse"},{"key":"10.1016\/j.vaccine.2019.12.042_b0155","doi-asserted-by":"crossref","unstructured":"Reinhardt B, Jaspert R, Niedrig M, Kostner C, L\u2019age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: A model of human flavivirus infection. J Med Virol 1998;56:159\u201367. doi:10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B.","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B"},{"key":"10.1016\/j.vaccine.2019.12.042_b0160","article-title":"A simple micro-culture method for the study of group B arboviruses","author":"De Madrid","year":"1969","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.12.042_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0149871","article-title":"A single 17D yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and T-cell responses after vaccination","volume":"11","author":"Wieten","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.042_b0170","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.vaccine.2016.01.037","article-title":"Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication","volume":"34","author":"Wieten","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.042_b0175","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Review article: Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.12.042_b0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jviromet.2005.08.001","article-title":"Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay","volume":"131","author":"Cohen","year":"2006","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2019.12.042_b0185","doi-asserted-by":"crossref","unstructured":"Ferreira C de C, Campi-Azevedo AC, Peruhype-Magalh\u0101es V, Coelho-dos-Reis JG, Antonelli LR do V, Torres K, et al. Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis. Arthritis Res Ther 2019. doi:10.1186\/s13075-019-1854-6.","DOI":"10.1186\/s13075-019-1854-6"},{"key":"10.1016\/j.vaccine.2019.12.042_b0190","first-page":"1","author":"Miyaji","year":"2017","journal-title":"Antibodies Prev Vacc Adults"},{"key":"10.1016\/j.vaccine.2019.12.042_b0195","first-page":"492","article-title":"Yellow fever","author":"Staples","year":"2011","journal-title":"Trop Infect Dis Princ Pathog Pract"},{"key":"10.1016\/j.vaccine.2019.12.042_b0200","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.042_b0205","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4049\/jimmunol.1402605","article-title":"CD8 + T cells complement antibodies in protecting against yellow fever virus","volume":"194","author":"Bassi","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.12.042_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004464","article-title":"Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe yellow fever virus infection in mice","author":"Bassi","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.042_b0215","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","article-title":"Booster dose after 10 years is recommended following 17DD-YF primary vaccination","volume":"12","author":"Campi-Azevedo","year":"2016","journal-title":"Hum Vacc Immun"},{"key":"10.1016\/j.vaccine.2019.12.042_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/s1678-9946201759002","article-title":"Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults","volume":"59","author":"Miyaji","year":"2017","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"10.1016\/j.vaccine.2019.12.042_b0225","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/1469-0691.12332","article-title":"Yellow fever revaccination guidelines change - A decision too feverish?","volume":"19","author":"Grobusch","year":"2013","journal-title":"Clin Microbiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:42:49Z","timestamp":1759401769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":45,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0264410X19316949"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.042","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}